Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
High-yield transgenic mammalian expression system for generating virus-like particles
US8980281B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980281-B2 |
| Application number | US-70492810-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 12, 2010 |
| Priority date | Sep 5, 2006 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.
First claim
Opening claim text (preview).
We claim: 1. A method of preparing an influenza virus-like particle (VLP) for a target influenza strain, the method comprising: (1) obtaining a founder Vero cell, wherein the founder Veto cell is stably transfected with a sequence encoding an influenza M1 and a sequence encoding an influenza M2 comprising the amino acid sequence of SEQ ID NO: 7; (2) constructing at least one recombinant DNA molecule comprising a sequence encoding an influenza hemagglutinin (HA) and a sequence en…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- A61K39/215Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8980281B2 cover?
- Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.
- Who is the assignee on this patent?
- Hsiao Pei-Wen, Wu Chia-Ying, Yeh Yi-Chun, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/215. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).